Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remission induction chemotherapy prior to allogeneic stem cell transplantation in high-risk AML
2014-003124-44Phase 3Completed
- Sponsor
- DKMS
- Start
- Jul 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mitoxantrone in acute myeloid leukemia (AML) (2 arms), sponsored by DKMS. Primary endpoint: Disease-free survival at day 56 after allogeneic stem cell transplantation. Started Jul 2014; status: completed.
02
Drugs
mitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-003124-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003124-44.